pharmaphorum19m
FDA starts review of first bronchiectasis drug candidate
The FDA has started a priority review of Insmed's brensocatib, which is pitching to become the first approved therapy for ...
JMP Securities maintains Cytokinetics stock with $78 target
JMP Securities reiterated its Market Outperform rating and $78.00 price target for Cytokinetics shares (NASDAQ:CYTK). This affirmation comes despite the stock experiencing a significant drop on ...